clinical trial · NCT06679101
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
GlaxoSmithKline·phase3·recruiting·n = 520
Multiple MyelomaNewly Diagnosed Multiple MyelomaBelantamab mafodotinLenalidomideDexamethasoneDaratumumab
brief summary
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
started
Dec 16, 2024
primary completion
Apr 28, 2031
completion
Apr 28, 2031
last updated
Apr 22, 2026
official title
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol